Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.

/PRNewswire/ -- Thea Pharma Inc. ("Thea"), the U.S. subsidiary of Europe's leading independent ophthalmic-focused pharmaceutical company, Théa, dedicated to...

Related Keywords

Petaluma ,California ,United States ,France ,Barbados ,America ,American ,Clin Ophthalmol ,Susan Benton ,Henri Chibret ,Thea Pharma ,Jason Bacharach ,Prevention National Center ,Mckesson ,A Patient Assistance Program ,Centers For Disease ,Prnewswire Thea Pharma Inc ,Thea Pharma Inc ,Health Technol ,American Glaucoma Society ,Office Visits For Glaucoma ,Health Statistics ,Drug Administration ,Multichannel News Release ,North Bay Eye Associates ,Thea Savings ,Thea Savings Card ,Patient Assistance Program ,Lens Use ,Full Prescribing Information ,Beaver Dam ,South America ,North Africa ,Pharma Inc ,Benzalkonium Chloride ,Preserved Latanoprost Ophthalmic Solution ,Primary Open Angle Glaucoma ,Ocular Hypertension ,Disease Control ,National Center ,Barbados Eye ,Cumulative Incidence ,Primary Open Angle Glaucoma Among Participants ,Ocular Hypertension Treatment Study After ,Ocular Hypertension Treatment Study ,Primary Open Angle ,